Skip to content

Psychopharmacology

ISSN 1432-2072, 0033-3158

637 papers in the library · 20,322 citations · publishing 1971-2026

Papers

Sort Most recent Most cited

An observational study on the sub-acute effects of mephedrone on mood, cognition, sleep and physical problems in regular mephedrone users

Psychopharmacology June 26, 2018 Lina E. Homman, Jessica Seglert, Michael John Morgan 38 citations

RATIONALE: Mephedrone (4-methylmethcathinone; 4-MMC) is a novel recreational drug similar to methylenedioxymethamphetamine (MDMA) and amphetamine. Several adverse effects have been reported, but little is known about its sub-acute effects. OBJECTIVES: To study sub-acute effects of mephedrone over a period of 9 days. METHODS: Recreational mephedrone users were recruited and followed over a time...

The effects of a combination of intravenous dexamethasone and ketamine on postoperative mood in patients undergoing laparoscopically assisted-gynecologic surgery

Psychopharmacology June 14, 2018 Cheol Lee, Juhwan Lee, Gilho Lee et al.

It has been known that anesthetic adjuvants such as dexamethasone or ketamine might change mood. This study aimed to investigate the effects of a single dose of each drug individually along with their combined usage on postoperative mood changes in patients undergoing gynecologic surgery. Two hundred ninety-seven patients randomly allocated were divided into three groups. Group K (n = 99)...

Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine

Psychopharmacology May 31, 2018 Kim P. C. Kuypers, E. B. de Sousa Fernandes Perna, Patrick C. Dolder et al. 14 citations

BACKGROUND: New psychoactive substances (NPS) are chemical analogues designed to mimic the effects of various classic recreational drugs of abuse including MDMA, LSD, and cannabis. NPS use is associated with concern about the acute and longer-term effects particular substances might have, with abuse and addiction as potential consequences. Impulsivity and sensitivity to the rewarding effects of...

DOI: 10.1007/s00213-018-4931-7 (opens in new tab) Full text (opens in new tab) Addiction Action physics Clinical psychology Cognitive psychology

Correction to: The hidden therapist: evidence for a central role of music in psychedelic therapy.

Psychopharmacology May 1, 2018 Mendel Kaelen, Bruna Giribaldi, Jordan Raine et al. 9 citations correction

The article The hidden therapist: evidence for a central role of music in psychedelic therapy, written by Mendel Kaelen, Bruna Giribaldi, Jordan Raine, Lisa Evans, Christopher Timmerman, Natalie Rodriguez, Leor Roseman, Amanda Feilding, David Nutt, Robin Carhart-Harris, was originally published electronically on the publisher's internet portal.

Altered orbitofrontal activity and dorsal striatal connectivity during emotion processing in dependent marijuana users after 28 days of abstinence.

Psychopharmacology March 2018 Kaeli Zimmermann, Shuxia Yao, Marcel Heinz et al.

Intact cognitive and emotional functioning is vital for the long-term success of addiction treatment strategies. Accumulating evidence suggests an association between chronic marijuana use and lasting alterations in cognitive brain function. Despite initial evidence for altered emotion processing in dependent marijuana users after short abstinence periods, adaptations in the domain of emotion...

Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats.

Psychopharmacology March 2018 Michael B. Gatch, Michael J Forster

Novel synthetic cannabinoid compounds continue to appear in the market advertised as legal alternatives to marijuana and the older synthetic cannabinoid compounds which are now controlled substances. Most of these newer compounds have been found to act at CB1 receptors, so the purpose of this study was to study the abuse liability of these compounds. Five of these compounds (BB-22, FUB-PB-22,...

DOI: 10.1007/s00213-017-4783-6 (opens in new tab) Full text (opens in new tab) Abuse liability Cannabinoids Drug discrimination Locomotor activity +2

The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task

Psychopharmacology February 22, 2018 S. Barnes, Jared W Young, A. Markou et al.

Attentional processing deficits are a core feature of schizophrenia, likely contributing to the persistent functional and occupational disability observed in patients with schizophrenia. The pathophysiology of schizophrenia is hypothesized to involve dysregulation of NMDA receptor-mediated glutamate transmission, contributing to disruptions in normal dopamine transmission. Preclinical...

The hidden therapist: evidence for a central role of music in psychedelic therapy

Psychopharmacology February 1, 2018 Mendel Kaelen, Bruna Giribaldi, Jordan Raine et al. 274 citations

Recent studies have supported the safety and efficacy of psychedelic therapy for mood disorders and addiction. Music is considered an important component in the treatment model, but little empirical research has been done to examine the magnitude and nature of its therapeutic role. The present study assessed the influence of music on the acute experience and clinical outcomes of psychedelic...

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Psychopharmacology February 1, 2018 Theresa M. Carbonaro, Matthew W Johnson, Ethan Hurwitz et al. 139 citations

Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared. This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects. Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and...

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

Psychopharmacology February 1, 2018 Randall L. Morrison, Maggie Fedgchin, Jaskaran Singh et al. 72 citations

BACKGROUND: The effect of intranasal esketamine on cognitive functioning in healthy participants is assessed in this study. METHODS: computerized test battery assessed at 1 h predose and 40 min, 2, 4, and 6 h postdose. Secondary measures included the Mental Effort Scale, Karolinska Sleepiness Scale (KSS), and safety. RESULTS: Esketamine was associated with significant cognitive performance...

DOI: 10.1007/s00213-018-4828-5 (opens in new tab) Full text (opens in new tab) Placebo Anesthesia Crossover study Adverse effect +2

Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.

Psychopharmacology February 1, 2018 John Hartberg, Simone Garrett-Walcott, Angelo De Gioannis 66 citations

Depressive episodes are the leading cause of mental health-related hospital admissions in Australia, and 44% of those admitted have a previous history of hospitalisations for depression (Admitted patient mental health-related care: (Australian Institute of Health and Welfare Aust Hospital Stat 2011-12, 2013). Despite numerous available antidepressant treatments, many patients do not respond to...

Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Psychopharmacology February 2018 Roger Hudson, Walter J Rushlow, Steven R Laviolette

Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type...

Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.

Psychopharmacology February 1, 2018 Liana Fattore, Alessandro Piva, Mary Tresa Zanda et al.

Clinical data with 3,4-methylenedioxymethamphetamine (MDMA) in post-traumatic stress disorder (PTSD) patients recently stimulated interest on the potential therapeutic use of psychedelics in disorders characterized by maladaptive memories, including substance use disorders (SUD). The rationale for the use of MDMA in PTSD and SUD is being extended to a broader beneficial "psychedelic effect,"...

DOI: 10.1007/s00213-017-4793-4 (opens in new tab) Full text (opens in new tab) Ketamine Cannabinoids Maladaptive memories Post-traumatic stress disorders +2

Regulation of human research with LSD in the United States (1949-1987).

Psychopharmacology February 2018 Katherine R. Bonson

Human research with hallucinogens such as lysergic acid diethylamide (LSD) has been ongoing in the USA since 1949. During the 1960s, LSD was investigated for a variety of psychiatric indications, including the following: as an aid in treatment of schizophrenia; as a means of creating a "model psychosis"; as a direct antidepressant; and as an adjunct to psychotherapy. Studies with all drugs,...

(±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Psychopharmacology February 2018 Elizabeth G Pitts, Daniel W Curry, Karly N Hampshire et al.

The use of (±)-3,4-methylenedioxymethamphetamine ((±)-MDMA) as an adjunct to psychotherapy in the treatment of psychiatric and behavioral disorders dates back over 50 years. Only in recent years have controlled and peer-reviewed preclinical and clinical studies lent support to (±)-MDMA's hypothesized clinical utility. However, the clinical utility of (±)-MDMA is potentially mitigated by a range...

Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Psychopharmacology February 2018 Elena Martín-González, Ángeles Prados-Pardo, Santiago Mora et al.

Clinical studies have shown that some psychoactive recreational drugs have therapeutic applications in anxiety, depression, and schizophrenia. However, to date, there are few studies on the therapeutic potential efficacy of recreational drugs in compulsive neuropsychiatric disorders. We explored the therapeutic potential of different psychoactive and psychedelic drugs in a preclinical model of...

DOI: 10.1007/s00213-017-4819-y (opens in new tab) Full text (opens in new tab) Compulsivity Psychedelic drugs Psychoactive drugs Schedule-induced polydipsia

Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers

Psychopharmacology January 5, 2018 Anna Bravermanová, Michaela Viktorinová, Filip Tylš et al. 50 citations

RationaleDisruption of auditory event-related evoked potentials (ERPs) P300 and mismatch negativity (MMN), electrophysiological markers of attentive and pre-attentive cognitive processing, is repeatedly described in psychosis and schizophrenia. Similar findings were observed in a glutamatergic model of psychosis, but the role of serotonergic 5-HT2A receptors in information processing is less...

Progress and promise for the MDMA drug development program.

Psychopharmacology November 20, 2017 Allison A. Feduccia, Julie Holland, Michael C Mithoefer 79 citations

Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs...

DOI: 10.1007/s00213-017-4779-2 (opens in new tab) Psychedelic therapy MDMA Therapy MDMA-Assisted Psychotherapy MDMA Treatment +21

Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication

Psychopharmacology November 16, 2017 Eline Haijen, Magı́ Farré, Rafael de la Torre et al. 9 citations

Preclinical data have suggested involvement of the endocannabinoid (eCB) system in MDMA-induced memory impairment. Clinical research has shown that blockade of the 5-HT 2 receptor nulls memory impairment during MDMA intoxication. Interestingly, studies have demonstrated that the eCB and the 5-HT system interact. It was hypothesized that MDMA would cause an increase in eCB concentrations...

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Psychopharmacology November 8, 2017 R. L. Carhart-Harris, Mark Bolstridge, C. M. J. Day et al. 978 citations

RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major...

Evaluation of training dose in male Sprague-Dawley rats trained to discriminate 4-methylmethcathinone.

Psychopharmacology November 2017 Michael D. Berquist, Nathyn A Thompson, Lisa E Baker

Although the synthetic cathinone 4-methylmethcathinone (4-MMC, mephedrone) has been a subject of intensive research investigation, the pharmacological mechanisms involved in its interoceptive stimulus effects have yet to be fully characterized. The present study employed drug discrimination methods in rats to compare the interoceptive stimulus properties of two different training doses of 4-MMC...

DOI: 10.1007/s00213-017-4716-4 (opens in new tab) Full text (opens in new tab) 4-mmc 4-methylmethcathinone Bath salts Drug discrimination +2

Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users.

Psychopharmacology November 2017 Chandni Hindocha, Will Lawn, Tom P. Freeman et al.

Cannabis and tobacco are often smoked simultaneously in joints, and this practice may increase the risks of developing tobacco and/or cannabis use disorders. Currently, there is no human experimental research on how these drugs interact on addiction-related measures. This study aimed to investigate how cannabis and tobacco, each alone and combined together in joints, affected individuals'...

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression

Psychopharmacology October 30, 2017 J. B. Stroud, Tom P. Freeman, Robert Leech et al. 102 citations

RATIONALE: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. OBJECTIVES: The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in treatment-resistant depression (TRD), alters patients' emotional processing biases. METHODS: Seventeen patients with...

Effects of GABA-B receptor positive modulator on ketamine-induced psychosis-relevant behaviors and hippocampal electrical activity in freely moving rats.

Psychopharmacology October 2017 Jingyi Ma, L Stan Leung

Decreased GABAB receptor function is proposed to mediate some symptoms of schizophrenia. In this study, we tested the effect of CGP7930, a GABAB receptor positive allosteric modulator, on ketamine-induced psychosis-relevant behaviors and hippocampal electrical activity in behaving rats. Electrodes were bilaterally implanted into the hippocampus, and cannulae were placed into the lateral...

DOI: 10.1007/s00213-017-4705-7 (opens in new tab) Full text (opens in new tab) Ketamine Cgp7930 Gabab receptor modulator Prepulse inhibition +1

Long-lasting subjective effects of LSD in normal subjects

Psychopharmacology September 16, 2017 Yasmin Schmid, Matthias E. Liechti 234 citations

RATIONALE: Lysergic acid diethylamide (LSD) and other serotonergic hallucinogens can induce profound alterations of consciousness and mystical-type experiences, with reportedly long-lasting effects on subjective well-being and personality. METHODS: We investigated the lasting effects of a single dose of LSD (200 μg) that was administered in a laboratory setting in 16 healthy participants. The...